Automated synthesis of an 18F-labelled pyridine-based alkylating agent for high yield oligonucleotide conjugation

Applied Radiation and Isotopes

Volumn 67, Issue 9, 2009, Pages 1670-1675

  von Guggenberg, Elisabeth ^a   Sader, Jayden A ^a   Wilson, John S ^a   Shahhosseini, Soraya ^a   Koslowsky, Ingrid ^a   Wuest, Frank ^a   Mercer, John R ^a  

^a Edmonton Radiopharmaceutical Centre   (Canada)

Author keywords

Alkylation; Automation; Fluorine 18; Modular synthesis unit; Oligonucleotides; Prosthetic group

Indexed keywords

ALKYLATING AGENTS; AUTOMATED SYNTHESIS; CHROMATOGRAPHIC ISOLATION; CLINICAL APPLICATION; FLUORINE-18; HIGH YIELD; MODULAR SYNTHESIS; MODULAR SYNTHESIS UNIT; OVERALL BENEFIT; PRECLINICAL STUDIES; PROSTHETIC GROUP; RADIOCHEMICAL YIELD; RADIOLABELLING; RAPID PURIFICATION; REACTION CONDITIONS; SOLID-PHASE EXTRACTION; SPECIFIC ACTIVITY;

ALKYLATION; AUTOMATION; EXTRACTION; FLUORINE; HYDROCARBONS; MUTAGENS; NUCLEIC ACIDS; OLIGONUCLEOTIDES; PROSTHETICS; PYRIDINE; RADIOISOTOPES;

SYNTHESIS (CHEMICAL);

2 BROMO N [3 (2 FLUOROPYRIDIN 3 YLOXY)PROPYL]ACETAMIDE F 18; 2 BROMO N [3 (2 FLUOROPYRIDIN3 YLOXY)PROPYL]ACETAMIDE F 18; 3 AZIDO 5 NITROBENZYL FLUORIDE F 18; 4(FLUOROMETHYL)PHENYL ISOTHIOCYANATEF 18; ALKYLATING AGENT; FLUORINE 18; N (4 FLUOROBENZYL) 2 BROMOACETAMIDE F 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; PYRIDINE; TRACER; UNCLASSIFIED DRUG; 2 BROMO N (3 (2 FLUOROPYRIDIN 3 YLOXY)PROPYL)ACETAMIDE; 2-BROMO-N-(3-(2-FLUOROPYRIDIN-3-YLOXY)PROPYL)ACETAMIDE; ACETAMIDE DERIVATIVE; FLUORINE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; AUTOMATION; CHEMICAL REACTION; CHROMATOGRAPHY; CONJUGATION; DNA SEQUENCE; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; CHEMISTRY; SYNTHESIS;

ACETAMIDES; ALKYLATING AGENTS; FLUORINE RADIOISOTOPES; OLIGONUCLEOTIDES; PYRIDINES; RADIOPHARMACEUTICALS;

EID: 67349203995     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.04.004     Document Type: Article

References (38)

1. 18F-fluorination of 1,N-disubstituted alkanes as fluoroalkylation agents. J. Labelled Compd. Radiopharm. 24 9 (1987) 1029-1042
2. 18F]-labelling of aliphatic compounds in high yields via aminopolyether-supported nucleophilic substitution. J. Labelled Compd. Radiopharm. 23 5 (1986) 467-477
3. Brody E.N., and Gold L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74 1 (2000) 5-13
4. de Vries E.F., Vroegh J., Elsinga P.H., and Vaalburg W. Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides. Appl. Radiat. Isotopes 58 4 (2003) 469-476
5. 18F for in vivo PET imaging. J. Labelled Compd. Radiopharm. 39 4 (1997) 319-330
6. Ellington A.D., and Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346 6287 (1990) 818-822
7. Gomzina N.G., Vasil'ev D.A., and Krasikova R.N. Optimization of automated synthesis of 2-[F]Fluoro-2-deoxy-d-glucose involving base hydrolysis. Radiochemistry 44 4 (2002) 366-372
8. 18F fluoroethyl)-L-tyrosine. Appl. Radiat. Isotopes 57 6 (2002) 853-856
9. 18F]Fluoromethyl)phenyl isothiocyanate and its use in labelling oligonucleotides. Acta. Chim. Scand. 51 (1997) 1236-1240
10. 18F]Fluorobenzoate. Acta. Chim. Scand. 52 (1998) 1034-1039
11. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J., Borkowski S., Hilger C.S., Cook G., Warren S., and Schmidt P.G. Tumor targeting by an aptamer. J. Nucl. Med. 47 4 (2006) 668-678
12. Hjelstuen O.K., Tønnesen H.H., Bremer P.O., and Verbruggen A.M. 3′-99mTc-labeling and biodistribution of a CAPL antisense oligodeoxynucleotide. Nucl. Med. Biol. 25 7 (1998) 651-657
13. Hnatowich D.J. Antisense and nuclear medicine. J. Nucl. Med. 40 4 (1999) 693-703
14. Javier D.J., Nitin N., Levy M., Ellington A., and Richards-Kortum R. Aptamer-targeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging. Bioconjugate Chem. 19 6 (2008) 1309-1312
15. 18F]fluorobenzyl]-2-bromoacetamide: an F-18-labeled reagent for the prosthetic radiolabeling of oligonucleotides. J. Labelled Compd. Radiopharm. 51 10 (2008) 352-356
16. Krasikova R. Synthesis modules and automation in F-18 labeling. Ernst. Schering. Res. Found. Workshop 62 (2007) 289-316
17. 18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nucl. Med. Biol. 35 2 (2008) 255-260
18. 18F]fluoropyridin-3-yloxy)propyl]acetamide. Bioconjugate Chem. 15 3 (2004) 617-627
19. Kuhnast B., Dollé F., Terrazzino S., Rousseau B., Loc′h C., Vaufrey F., Hinnen F., Doignon I., Pillon F., David C., Crouzel C., and Tavitian B. General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies. Bioconjugate Chem. 11 5 (2000) 627-636
20. Kuhnast B., Klussmann S., Hinnen F., Boisgard R., Rousseau B., Furste J.P., Tavitian B., and Dollé F. Fluorine-18- and iodine-125-labelling of spiegelmers. J. Labelled Compd. Radiopharm. 46 13 (2003) 1205-1219
21. 18F]fluoride to an oligonucleotide aptamer. J. Labelled Compd. Radiopharm. 45 3 (2002) 257-268
22. 18F]fluorobenzoate using a Siemens/CTI chemistry process control unit [CPCU]. Appl. Radiat. Isotopes 65 2 (2007) 199-203
23. 18F]FDG module. Nucl. Med. Biol. 32 8 (2005) 899-905
24. 2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images. Nanomedicine 4 3 (2008) 201-207
25. Perkins A.C., and Missailidis S. Radiolabelled aptamers for tumour imaging and therapy. Q. J. Nucl. Med. Mol. Imaging. 51 4 (2007) 292-296
26. 18F]FAZA: reaction parameters and automation. Appl. Radiat. Isotopes 62 6 (2005) 897-901
27. 18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl. Med. Biol. 32 2 (2005) 109-116
28. Satyamurthy N., Phelps M.E., and Barrio J.R. Electronic generators for the production of positron-emitter labeled radiopharmaceuticals. Where would PET be without them?. Clin. Positron Imaging 2 5 (1999) 233-253
29. 18F]F-A-85380). Appl. Radiat. Isotopes 65 11 (2007) 1244-1248
30. Tamm I., Dörken B., and Hartmann G. Antisense therapy in oncology: new hope for an old idea?. Lancet 358 9280 (2001) 489-497
31. Tavitian B. In vivo imaging with oligonucleotides for diagnosis and drug development. Gut 52 Suppl IV (2003) iv40-iv47
32. Tewson T., and Watkins G.L. Tweaking the FLT synthesis: modifications that improve the yield. J. Nucl. Med. 42 5 (2001) S257
33. WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer. Res. 60 3 (2000) 679-684
34. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 4968 (1990) 505-510
35. Viel T., Kuhnast B., Hinnen F., Boisgard R., Tavitian B., and Dollé F. Fluorine-18 labelling of small interfering RNAs (siRNAs) for PET imaging. J. Labelled Compd. Radiopharm. 50 13 (2007) 1159-1168
36. Wester H.J., and Schottelius M. Fluorine-18 labeling of peptides and proteins. Ernst. Schering. Res. Found. Workshop 62 (2007) 79-111
37. 76Br]bromobenzoate and its use in conjugation labeling of macromolecules. Acta. Chim. Scand. 53 (1999) 508-512
38. Younes C.K., Boisgard R., and Tavitian B. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr. Pharm. Des. 8 16 (2002) 1451-1466